Fate Therapeutics Inc (FATE NASDAQ) stock market data APIs
$1.0697
0.03(2.8%)
as of July 7, 2025
Try our APIs with
free plan!
Fate Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Prev. Close
1.0697
Open
1.0952
High
1.1383
Low
1.0462
52 wk Range
0.6611-5.92
Market Cap
128 M
Shares Outstanding
115 M
Revenue
13 335 K
EPS
-0.32
Beta
2.231
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Fate Therapeutics Inc data using free add-ons & libraries
Get Fate Therapeutics Inc Fundamental Data
Fate Therapeutics Inc Fundamental data includes:
- Net Revenue: 13 335 K
- EBITDA: -168 276 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.3794
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Fate Therapeutics Inc News
New
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline...
H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5
Investing.com - H.C. Wainwright has reiterated its Neutral rating and $5.00 price target on Fate Therapeutics (NASDAQ:FATE), currently trading at $1.14, following the company’s presentation of FT819...
Fate Therapeutics' SWOT analysis: promising data boosts stock outlook
Fate Therapeutics, Inc. (NASDAQ:FATE), a biotechnology company specializing in cellular immunotherapies, has been making significant strides in the development of treatments for cancer and autoimmune ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
